News
12-18-2007, 04:01 AM
After approximately 8 years, postmenopausal women withhormone-sensitive breast cancer who received (Arimidex),generically known as anastrazole, had a lower risk of recurrencethan women taking tamoxifen, investigators reported at the annualmeeting of the San Antonio Breast Cancer Symposium.
More... (http://www.healthcentral.com/breast-cancer/news-197462-66.html)
More... (http://www.healthcentral.com/breast-cancer/news-197462-66.html)